Close Menu

NEW YORK (GenomeWeb) – Optivia Biotechnologies and cell-based assays firm Hurel today announced they have reached a technology and marketing alliance..

The partnership will give researchers an array of powerful tools for in vitro studies of hepatic clearance and drug-induced liver injury, the firms said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.